Promising combo for tough blood cancers halted early — only 4 patients enrolled
NCT ID NCT00776373
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested whether adding rapamycin to high-dose chemotherapy could help people with aggressive blood cancers (like certain leukemias and lymphomas) that had returned or not responded to prior treatment. Only 4 adults aged 18–65 took part before the study was stopped early. The goal was to check safety and whether the combination could control the disease, but results are limited due to the small size.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADULT T-CELL LEUKEMIA/LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Pennsylvania Abramson Cancer Center
Philadelphia, Pennsylvania, 19066, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a smart drug missile tame Hard-to-Treat leukemia?
- Can a targeted antibody boost chemotherapy against a rare leukemia?
- Can pressurized oxygen boost cord blood transplants?
- New drug combo aims to make stem cell transplants safer for blood cancer patients
- Can a children's chemo recipe help adults with leukemia? early trial adds venetoclax to the mix.
- Exercise during chemo: new study tests strength training for children with leukemia